In September 2019, the company closed a £100 million ($120.6 million) Series B financing led by incoming US investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.

Proceeds from this financing, which was over-subscribed, will deliver two human proof-of-concept studies in non-small cell lung cancer and melanoma.